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ABSTRACT  
Background. The primary hurdle for the eradication of HIV-1 is the establishment of a latent viral 
reservoir early after primary infection. Here we investigated the potential influence of human 
genetic variation on the HIV-1 reservoir size and its decay rate during suppressive antiretroviral 
treatment (ART). 
Setting. Genome-wide association study and exome sequencing study to look for host genetic 
determinants of HIV-1 reservoir measurements in patients enrolled in the Swiss HIV Cohort Study 
(SHCS), a nation-wide prospective observational study.     
Methods. We measured total HIV-1 DNA in peripheral blood mononuclear cells from study 
participants, as a proxy for the reservoir size, at three time points over a median of 5.4 years, and 
searched for associations between human genetic varation and two phenotypic readouts: the 
reservoir size at the first time point and its decay r te over the study period. We assessed the 
contribution of common genetic variants using genome-wide genotyping data from 797 patients 
with European ancestry enrolled in the Swiss HIV Cohort Study and searched for a potential impact 
of rare variants and exonic copy number variants using exome sequencing data generated in a 
subset of 194 study participants.  
Results. Genome- and exome-wide analyses did not reveal any sig ificant association with the size 
of the HIV-1 reservoir or its decay rate on suppressive ART.  
Conclusions. Our results point to a limited influence of human genetics on the size of the HIV-1 
reservoir and its long-term dynamics in successfully treated individuals.   
 
Key words: HIV, genetics, ART, latent reservoir, GWAS, exome sequencing 
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INTRODUCTION 
Combination antiretroviral treatment (ART) has turned the previously lethal infection by human 
immunodeficiency virus type 1 (HIV-1) into a chronic disease. Despite this significant achievement, 
HIV-1 as retrovirus, self-integrating its genome into the host chromosome, persists indefinitely in 
infected individuals during treatment,1–4 and life-long ART is required to control the infection.  
A major hurdle to HIV-1 eradication is the establishment, already during primary infection, of a 
latent viral reservoir of HIV-1 DNA persisting as provirus in resting memory CD4+ T cells.1,2,5–8 At 
the molecular level, chromatin remodeling, epigenetic modifications, transcriptional interference, 
and availability of transcription factors have been co sidered as possible mechanisms contributing 
to HIV-1 latency.9 The viral reservoir is measurable through different methods, including viral 
outgrowth assay and intracellular HIV-1 DNA quantification.10,11 Currently, there is no consensus 
on the best HIV-1 reservoir biomarker. Viral outgrowth assays only measure replication-competent 
proviruses and have therefore been considered to be the gold standard to measure the latent 
reservoir.12 Total cell-associated HIV-1 DNA measurements quantify both integrated and 
nonintegrated viral genomes coding for intact or defective viruses,13 thus detecting higher infected-
cell frequencies compared to those obtained with viral outgrowth assays.12,14 Importantly, HIV-1 
DNA measurement is easy to measure in different cell and tissue samples and is applicable to large 
populations, and has been shown to be a good proxy for the reservoir size.15 Total HIV-1 DNA 
levels have been shown to correlate with viral outgrowth,16 and to predict the time to viral rebound 
at treatment interruption.17 Moreover, the substantial loss of nonintegrated HIV-1 DNA genomes 
following ART initiation suggests that total HIV-1 DNA after prolonged suppression is largely 
accounted for by integrated viral genomes.18  
After an initial rapid decay following ART initiation, changes of the viral reservoir size over time 
display wide inter-individual variability. By limiting dilution culture assay, the half-life of the viral 
reservoir was first estimated to be 44 months (95% confidence interval 27.4-114.5) in individuals 
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with undetectable viremia.4 A more recent study, based on total HIV-1 DNA quantification, showed 
a slow decline with a half-life of 13 years after the first four years of suppressive ART.19 Generally, 
different culture-based and PCR-based studies show a broad variability of the average decay rate, 
from 2.5 months to no measurable decay.20–28 One study even reported an increase in the viral 
reservoir size, as measured by total HIV-1 DNA quantification, in as much as 31% of patients in the 
4-7 years following ART initiation,29 and recent data from our group confirm this observation, 
reporting an increase in the reservoir size in 26.8% of individuals in the 1.5-5.5 years after ART 
initiation.30  
Several factors are known to influence the decay rate of the viral reservoir: initiation of ART during 
acute HIV-1 infection substantially accelerates thedecay rate, while viral blips and low-level 
viremia during ART slow it down, as shown in previous studies and in recent data from our 
cohort.24,30 Conversely, treatment intensification, i.e.  treating with additional drugs, does not appear 
to influence the decay rate, suggesting that residual replication is not the main driver of the viral 
reservoir or that it may happen in sanctuary sites.31  
Human genetic variants have been shown to influence the outcome of various infections, including 
HIV. Previous genome-wide association studies (GWAS) addressed the role of common genetic 
polymorphisms in several HIV-related phenotypes, including plasma viral load (HIV-1 RNA) at set 
point, exceptional capacity to control viral replication, pace of CD4+ T lymphocyte decline, time to 
clinical AIDS, rapid progressor status or long-term non-progressor status (LTNP),32–39 and, in one 
single study, the amount of intracellular HIV-1 DNA, measured at a single time point during the 
chronic phase of infection.40 Rare genetic variants that are detectable through DNA sequencing 
technologies have been investigated far less. However, a large exome sequencing study did not 
reveal any convincing association of such variants with the natural history of HIV disease.41  
To date, no studies have addressed the role of human genetic variation in determining the initial 
viral reservoir size and the reservoir decay rate over time. In the current study, we searched for host
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genetic factors associated with the HIV-1 reservoir size and its long-term dynamics in a cohort of 
797 HIV-1 positive individuals on suppressive ART for at least five years.  
 
 
METHODS   
Ethics statement  
The Swiss HIV Cohort Study (SHCS) was approved by the local ethical committees of the 
participating centres: Kantonale Ethikkommission Zürich (KEK-ZH-NR: EK-793); 
Ethikkommission beider Basel (“Die Ethikkommission beider Basel hat die Dokumente zur Studie 
zustimmend zur Kenntnis genommen und genehmigt.”); Kantonale Ethikkommission Bern (21/88); 
Comité departmental d’éthique des specialités médicales es de médecine communautarie et de 
premier recours, Hôpitaux Universitaires de Genève (01–142); Commission cantonale d’éthique de 
la recherche sur l’être humain, Canton de Vaud (131/01); Comitato etico cantonale, Repubblica e 
Cantone Ticino (CE 813); Ethikkommission des Kantons St. Gallen (EKSG 12/003), and written 
informed consent was obtained from all participants. 
 
Study participants 
The SHCS is an ongoing, nation-wide cohort study of HIV-positive individuals, including more 
than 70% of all persons living with HIV in Switzerland. Clinical and laboratory information has 
been prospectively recorded at follow-up visits every 3-6 months since 1988.42 The general 
enrolment criteria have been described previously.30 Additionally, availability of genome-wide 
genotyping data from previous studies or of a DNA sample for genotyping was required for 
inclusion in this study (Figure 1). 
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Quantification of total HIV-1 DNA 
The collection of longitudinal cryopreserved peripheral blood mononuclear cells (PBMCs) from 
eligible participants and the quantification of total HIV-1 DNA by droplet digital PCR has been 
described previously along with the calculation of the reservoir decay rate by linear regression.30  
Briefly, this study utilized total HIV-1 DNA quantifications from three time points at a median of 
~1.5 years, ~3.5 years, and ~5.4 years after initiation of ART.  
 
Genotyping and genome-wide association analyses 
Genome-wide genotyping data were obtained from previous GWAS generated using various 
microarrays, or generated from DNA extracted from peripheral blood mononuclear cells using the 
HumanOmniExpress-24 BeadChip (Illumina Inc., San Diego, CA, USA). Genotypes from each 
genotyping array were filtered and imputed separately, study participants were filtered based on 
European ancestry as determined by principal component analysis (PCA) and imputed variants were 
filtered by minor allele frequency (MAF) < 5%, missingness > 10%, deviation from Hardy-
Weinberg equilibrium (PHWE < 1e-6) and imputation quality score (INFO < 0.8). The remaining 
genotypes were then combined using PLINK (v1.90b5) prior to analyses.43  
To carry out the GWASs, genome-wide genotypes were test d for association with each of the two 
study phenotypes (reservoir size or reservoir decay rate) in two separate genome-wide association 
analyses. Statistical significance was set to the sandard genome-wide significance threshold of P < 
5e-8 to correct for multiple testing, and covariates where included to assess the contribution of 
variables previously shown to be associated with eit er reservoir size or decay rate. Classical HLA 
alleles at the four-digit level and variable amino acids within HLA proteins were imputed and 
studied for association with the study phenotypes. With our sample size, we had 80% power to 
detect variants with a MAF of 10% explaining at least 5% of the variance in HIV-1 reservoir size or 
decay rate.44 
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Genotypes at specific loci, i.e. the CCR5∆32 deletion (rs333) and the HLA-B*57:01 allele, known 
to influence the setpoint viral load (spVL),45,46 were also tested for association with the reservoir 
size and its decay rate in 797 patients. A detailed description of genotyping and GWAS is available 
in the online methods in the Supplemental Digital Content,http://links.lww.com/QAI/B521. 
 
Exome sequencing and analysis 
After capture and sequencing of all coding exons, sequence reads were processed according to 
genome analysis toolkit (GATKv3.7) best practices, quality filtered and annotated with SnpEff 
(v4.3T).47 
The multi-sample VCF file was used for single variant ssociation analyses using PLINK for 
common variants and optimal sequence kernel association tests (SKAT-O) for rare variants.48 For 
the decay rate, individuals were split into two groups due to the non-normal distribution, one 
exhibiting a very high decay over time (< -0.03 -log10(DNA)) and another with a stable reservoir 
size (≥ -0.03 and ≤ 0.03 -log10(DNA)). For this case-control analysis we used the SKATbinary 
function with linear weighted variants as implemented in the SKAT R package. For association 
analyses, the 4-digit HLA alleles were extracted and analyzed using PyHLA.49 A detailed 
description of exome sequencing and analysis is available in the online methods in the 
Supplemental Digital Content,http://links.lww.com/QAI/B521.  
 
Copy number variation 
Copy number variations (CNVs) were called from exome sequencing data using CLAMMS and 
studied for association with the study phenotypes.50 A detailed description of CNV analysis is 
available in the online supplemental digital content,http://links.lww.com/QAI/B521. 
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Statistical analyses 
All statistical analyses were performed using the R statistical software (v3.5.2), unless otherwise 
specified. 
 
RESULTS  
Host genetic determinants of the reservoir size and long-term dynamics 
To investigate the effects of host genetic variation on the size of the HIV-1 reservoir 1.5 years after 
ART initiation and its long-term dynamics under ART over a median duration of 5.4 years, we 
performed a GWAS, including 797 well-characterized HIV-1 positive individuals. All study 
participants were enrolled in the SHCS and were of European ancestry with longitudinal total HIV-
1 DNA measurements available (Table 1). The median HIV-1 reservoir size was 2.76 (IQR: 2.48-
3.03) log10 total HIV-1 DNA copies/1 million genomic equivalents measured ~1.5 years after 
initiation of ART (IQR: 1.3–1.7) (Figure S2A, Supplemental Digital 
Content,http://links.lww.com/QAI/B521). The median decay rate between 1.5-5.4 years after 
initiation of ART was -0.06 (IQR: -0.12-0.00) log10 total HIV-1 DNA copies/1 million genomic 
equivalents per year (Figure S2B, Supplemental Digital Content,http://links.lww.com/QAI/B521), 
which is equivalent to a half-life of 5 years on a linear scale. We found no significant sex 
differences in the reservoir size 1.5 years after initiation of ART or in the decay rate (Figure S3, 
Supplemental Digital Content,http://links.lww.com/QAI/B521).  
First, we performed GWAS using age and sex as covariates. We did not observe any genome-wide 
significant variant (P < 5e-8) associated with eithr HIV-1 reservoir size or long-term dynamics 
(Figure 2 and S4, Supplemental Digital Content,http://links.lww.com/QAI/B521). However, as we 
have previously determined, multiple factors are associated with the HIV-1 reservoir size and its 
decay rate,30 some of which are correlated (Figure S5, Supplemental Digital 
Content,http://links.lww.com/QAI/B521). Thus, we performed additional analyses iteratively 
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including these factors to test whether they could mask genetic associations. We ran multiple 
GWAS each adjusting for age, sex, plus one of the associated covariates, as well as all of the 
covariates together. The addition of the covariates did not have any significant effect on the results 
nor the genome-wide inflation factor (lambda) (Table S1, Supplemental Digital 
Content,http://links.lww.com/QAI/B521). 
Genetic variation in the HLA region has previously been associated with multiple HIV-related 
outcomes, including spVL.46 To test whether specific HLA variants were associated with reservoir 
size or long-term dynamics, we imputed the HLA alleles and amino acids for all 797 individuals 
from the genotyping data. In line with the previous re ults, we did not observe any genome-wide 
significant associations with any HLA allele or amino acid.  
 
Impact of protein-coding and rare variants 
To assess the impact of rare variants as well as protein-coding variants missed by genotyping arrays 
on the HIV-1 reservoir size and long-term dynamics, we performed exome sequencing in 194 of the 
797 study participants. Patients were selected at the wo extremes of the observed reservoir decay 
rate: either very rapid, or absent (no change in reservoir size over ~5.4 years), while individuals 
with increasing HIV-1 reservoir sizes were excluded (N=12). Thus, the long-term dynamics 
phenotype was binarized for subsequent analyses of the decay rate, while the HIV-1 reservoir size 
phenotype remained normally distributed (Figure S6, Supplemental Digital 
Content,http://links.lww.com/QAI/B521).  
To ensure that no common variants, missed by the genotype chips, were associated with the HIV-1 
reservoir size or long-term dynamics, we performed a GWAS for common variants using age and 
sex as covariates. As with the genotyping data, we observed no genome-wide significant variants 
for either phenotype (Figure S7, Supplemental Digital Content,http://links.lww.com/QAI/B521).   
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We then examined the potential role of rare variants (MAF < 5%) with a functional impact defined 
as either missense, frameshift, stop gained, splice ac ptor or donor.  Since HIV-1 primarily infects 
CD4+ T cells, we only included variants within genes expressed in these cells as determined by 
Gutierrez-Arcelus et al..51 The significance threshold after correcting for the number of tests 
performed was P = 1.21e-5. We did not observe any significant associations for either the HIV-1 
reservoir or the decay rate. The AMBRA1 gene showed the strongest association with HIV-1 
reservoir size (P = 4.15e-5, not significant) (Figure S8, Supplemental Digital 
Content,http://links.lww.com/QAI/B521).     
To confirm the lack of HLA association seen with the genotyping data, we imputed the HLA 
haplotypes from the exome data using HLA*LA. Again, we did not observe any significant HLA 
association with the study outcomes.   
 
Copy number variations 
To examine the role of large exonic CNVs not captured by standard genotyping and exome 
pipelines, we called CNVs from the mapped sequencing reads of the exome samples using the 
software CLAMMS. The contribution of common CNVs to HIV-1 reservoir size and long-term 
dynamics was analyzed by association analyses includi g age, sex and the first principal component 
as covariates. No significant association was observed after Bonferroni correction (Figure S9, 
Supplemental Digital Content,http://links.lww.com/QAI/B521). We also searched for rare CNVs in 
curated immune-related genes from Immport but did not discover any suggestive immune-related 
CNVs.52  
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Influence of HLA-B*57:01 and the CCR5∆32 deletion on reservoir size and long-term 
dynamics 
We have previously shown that pre-ART RNA viral load levels are associated with the HIV-1 
reservoir size and the occurrence of blips.30 The HLA-B*57:01 allele and the CCR5∆32 deletion are 
well known genetic variants influencing HIV-1 spVL,45,46 and could thus also be associated with the 
with the HIV-1 reservoir size or its decay rate. However, we did not observe any nominal 
association (all P > 0.05) with either reservoir size or its long-term dynamics for HLA-B*57:01 and 
CCR5∆32 (Figure S10, Supplemental Digital Content,http://links.lww.com/QAI/B521).   
 
 
DISCUSSION 
We used a combination of genomic technologies to assess the potential role of human genetic 
factors in determining both the HIV-1 reservoir size and its long-term dynamics in a well-
characterized, population-based cohort. We studied 797 HIV-1-positive individuals of European 
origin under suppressive ART over a median of 5.4 years, for whom extensive clinical data are 
available, allowing detailed characterization and correction for potential confounders.30 We 
measured the HIV-1 reservoir size at three time points and selected two phenotypes for our genomic 
study: the reservoir size at ~1.5 years after ART initiation and the slope of the reservoir decay rate
calculated over the three time points. Previous HIV host genetic studies mostly focused on 
phenotypes reflecting the natural history of HIV-1 infection, prior to ART initiation, including 
spontaneous viral control and disease progression.32–39 A single study specifically tested for 
associations between common genetic variants and the amount of intracellular HIV-1 DNA, 
measured at a single time point during the chronic phase of infection prior to initiation of any 
antiretroviral therapy.40 Here, in contrast, we longitudinally assessed samples collected from 
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patients under suppressive ART to search for human ge etic determinants of the long-term 
dynamics of the HIV-1 reservoir during treatment.  
We first conducted a GWAS on 797 individuals to test for association between common genetic 
variants and the phenotypes. The SHCS predominately consists of individuals of European ancestry 
(66.1%)42, which, in our cohort, accounted for 80% (797 out f 995) of individuals fulfilling the 
eligibility criteria and successfully genotyped (Figure 1). Given the small proportion of non-
European subjects in the initial study cohort, we only included patients of European ancestry to 
avoid any false positive associations or masking of true positive associations due to different allele 
frequencies in small proportions of individuals belonging to different subpopulations (Figure 1).53 
Our results are therefore applicable primarily to individuals of European ancestry.  
Regardless of including or not independent covariates other than the standard ones (i.e., sex and 
age), no genetic variant reached the genome-wide significance threshold for association with any of 
the two phenotypes. This may reflect a small effect size of genetic variants on the HIV-1 reservoir 
size and decay rate. We acknowledge that a larger sample size and thus increased statistical power 
may allow detecting genetic variants with a smaller effect size associated with the phenotypes. 
However, it should be noted that this study is by far the largest today that has investigated the size 
and decay of the HIV-reservoir in well characterized and well suppressed HIV-positive individuals 
over a longer time period.  Alternatively, the contr l of the HIV-1 reservoir size and its long-term 
dynamics may be under the control of viral or host factors other than the individual germline 
genetic background. A previous report from our group had shown a correlation between viral blips 
during the first 1.5 years of suppressive ART and the HIV-1 reservoir size 1.5 years after ART 
initiation, and between viral blips after 1.5-5.4 years of suppressive ART or low-level viremia and a 
slower decay rate.30 Importantly, viral blips are generally thought to reflect transient increases in 
viral replication, and probably occur under multifactorial influence from viral and host factors,54–61 
with these latter possibly including, but not being limited to, germline genetic variation. The 
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biological relations between viral reservoir, decay r te, viral blips, and the contribution of the 
individual genetic background still need full elucidation.  
Standard GWAS is designed to detect associations with common genetic variants (i.e., with a MAF 
of at least 0.05), with little power to investigate the role of rare variants. Thus, to further assess the 
contribution of rare variants in individuals at the extreme of the decay rate distribution, we used 
exome sequencing in a selected subset of 194 study participants with very high decay rate, or 
conversely, a stable reservoir size over time (Figure S6, Supplemental Digital 
Content,http://links.lww.com/QAI/B521). Here again, our analyses did not detect significant 
associations with the phenotypes. Although not reaching statistical significance, a rare genetic 
variant with potential functional impact in AMBRA1 had a p-value for association just below the 
corrected threshold. The expression of AMBRA1, a core component of the autophagy machinery, 
has previously been associated with long-term viral control in HIV-1 non-progressors.62 Future 
studies may further elucidate whether genetic variation in AMBRA1 may account for inter-
individual differences in the long-term dynamics of the HIV-1 reservoir.  
Large deletions or duplications of genomic material m y be implicated in human phenotypes, with 
CNVs impacting the exonic regions being more likely to have a functional role. Thus, we further 
investigated whether any common or rare CNV spanning exonic regions was associated with the 
phenotype.  Again, no CNV was statistically associated with the phenotypes both in the exome-
wide analyses and in analyses focused on immune-related genes.  
An inherent limitation of our exome-based association analyses was their inability to detect rare 
variants outside the coding or splice-site regions. The exonic regions account for approximately 1-
2% of the whole human genome. Because many regulatory sequences are located in extra-genic 
sites, our analysis did not fully investigate the role of highly conserved, non-coding genetic regions 
in influencing the phenotypes linked to HIV-1 latency. 
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Additionally, we focused on specific genetic variants, i.e., the HLA haplotypes and the CCR5∆32 
deletion, previously demonstrated to have a role in HIV-1 related phenotypes.32,46 Indeed, previous 
studies unraveled a robust association between variation in the HLA region and the HIV-1 spVL.32 
Likewise, heterozygosity for the CCR5∆32 deletion has been shown to influence spontaneous HIV-
1 control,46 Thus, we imputed HLA genotypes from genotyping andexome data, and studied the 
CCR5∆32 deletion, without, however, detecting any significant associations with the phenotypes or 
the covariates (Figure S9, Supplemental Digital Content,http://links.lww.com/QAI/B521).  
Specifically, we found no correlation between HLA genotypes and HIV-1 RNA plasma levels prior 
to ART initiation, apparently contrasting with the previous findings of an association between 
HLA-B*57:01 haplotype and spVL. This probably reflects historical changes in the therapeutic 
approach following a diagnosis of HIV-1 infection, given that ART is currently initiated soon after 
clinical diagnosis, before most patients reach a stable plateau of plasma viral load.   
In our study, the quantification of the reservoir size at different time points may have been 
influenced by factors as, for example, blips and low- evel viremia, which may have reduced our 
ability to detect significant genetic effects. It is also possible that, in the future, novel methods t  
assess the viral reservoir will allow the detection of significant contributions of genetic factors, a 
there is still ongoing debate on the optimal method to quantify the HIV-1 reservoir.13,63 PCR-based 
methods, measuring both replication-competent and defective proviruses,13 have been considered by 
some to overestimate the reservoir size compared to cul ure-based viral outgrowth assays, detecting 
replication-competent proviruses only.12,14 Despite the practical difficulties in determining the exact 
reservoir size at a given time point in an HIV-1 infected individual, and the inherent limitations of 
each quantification method, several aspects make total cell-associated HIV-1 DNA from PBMCs a 
reliable proxy. In our previous study, total cell-associated HIV-1 DNA independently correlated 
with time to initiation of ART, CD4+ cell counts, and viral blips,30 and the decay of the total HIV-1 
DNA that we observed was consistent with that observed in smaller studies using either viral 
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outgrowth assays or total HIV-1 DNA.1,4 In addition, defective genomes have been shown to be 
capable of transcribing novel unspliced forms of HIV-RNA during cART64, suggesting a biological 
relevance for both replication-competent and defectiv  proviruses. A recent study, published after 
the completion of our analyses, proposed a novel method to differentially quantify replication-
competent and defective proviruses,13 paving the way for novel studies investigating thedifferent 
roles of the two components of the viral DNA.  
So far, it remains unanswered whether the initial response to acute infection, the containment of 
ongoing replication, and the control of latently infected cells are under the influence of the same or 
different molecular networks. It needs to be noted that in previous work we have shown that host 
genetic factors as defined by GWAS did not explain the severity of symptoms during acute HIV-
infection, although severity of symptoms correlated well with viral load and CD4 cell counts.65  
In conclusion, our study suggests that human individual germline genetic variation has little, if any, 
influence on the control of the HIV-1 viral reservoir size and its long-term dynamics. Complex, 
likely multifactorial biological processes govern HIV-1 viral persistence. Larger genomic studies, 
taking into account defined biological phenotypes and the differential biological importance of 
replication-competent and defective proviruses, will possibly clarify the role of common or rare 
genetic variants explaining small proportions of the variability of the phenotypes related to viral 
latency.  
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FIGURE CAPTIONS 
Figure 1. Patient selection flowchart. Specific inclusion and exclusion criteria are listed for each 
selection step. ART (antiretroviral therapy); PBMCs (peripheral blood mononuclear cells); PI 
(protease inhibitor); PCA (principal component analysis). 
 
Figure 2. Association results with HIV-1 reservoir size. Manh ttan plot with association p-values (-
log10(P)) per genetic variant plotted by genomic position. Dashed line indicates the threshold for 
genome-wide significance (P = 5e-8). No variants were found to be genome-wide significant.    
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TABLE 1 
Table 1. Patient characteristics   
Total number of individuals 
 
  Genotyped 797 
  Genotyped + exome sequenced 194 
Age at first HIV-1 DNA sample in years    
   median (IQR) 44 (38, 50) 
Sex    
   Female 123 (15.4%) 
   Male 674 (84.6%) 
Transmission group    
   HET 241 (30.2%) 
   IDU 77 (9.7%) 
   MSM 448 (56.2%) 
   Other 31 (3.9%) 
HIV-1 subtype    
   B 550 (69.0%) 
   Non-B 128 (16.1%) 
   Unknown 119 (14.9%) 
Occurrence of blips or low-level viremia    
   Blips 200 (25.1%) 
   Low-level viremia 68 (8.5%) 
   None 529 (66.4%) 
Time on ART    
   median (IQR) 1.50 (1.28, 1.69) 
Infection stage    
   Acute 140 (17.6%) 
   Chronic 657 (82.4%) 
Time to viral suppression    
   median (IQR) 0.34 (0.23, 0.51) 
Log10 HIV-1 plasma RNA pre-ART per mL    
   median (IQR) 480 (248, 684) 
CD4+ cell count pre-ART cells/µL blood    
   median (IQR) 186 (90, 270) 
HIV-1 reservoir size    
   median (IQR) 2.76 (2.48, 3.03) 
HIV-1 reservoir decay rate    
   median (IQR) -0.06 (-0.12, -0.00) 
Transmission group indicates the self-reported route of infection (heterosexual (HET), 
intravenous drug usage (IDU), men who have sex with men (MSM), and other (including 
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transfusions and unknown)). The occurrence of viral blips was defined by measurements of ≥ 
50 HIV-1 RNA copies/mL plasma within a 30-day window. Individuals with consecutive 
measurements of ≥ 50 HIV-1 RNA copies/mL plasma for longer durations were classified as 
exhibiting low-level viremia. Time to viral suppression was the time from initiation of ART 
to the first viral load measurement below 50 copies/mL HIV-1 plasma RNA. HIV-1 reservoir 
size was measured in log10 total HIV-1 DNA/1 million genomic equivalents ~1.5 years after 
initiating ART. The HIV-1 reservoir decay rate was based on the three measurements of total 
HIV-1 DNA levels taken at the median of 1.5, 3.5 and 5.4 years after initiation of ART. 
 
AC
CE
PT
ED
Copyright  20 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited. 20
 
AC
CE
PT
ED
Copyright  20 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited. 20
 
AC
CE
PT
ED
Copyright  20 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited. 20
